Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nasal mucosa

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: Nasal mucosa. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2015-005155-27 Sponsor Protocol Number: KCT09/2015-SeptaNazal-Double Start Date*: 2017-02-22
    Sponsor Name:Krka, d.d., Novo mesto
    Full Title: Comparison of the efficacy and safety of the fixed-dose combination of xylometazoline and dexpanthenol in SeptaNazal® and xylometazoline in nasal congestion in patients after surgery in the nose an...
    Medical condition: Nasal congestion in patients after nasal surgery or nasal cavities surgery and in patients with acute rhinitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10028736 Nasal congestion and inflammations HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004921-41 Sponsor Protocol Number: P06332 Start Date*: 2015-02-24
    Sponsor Name:Corporation Schering-Plough K.K.
    Full Title: Multicenter, double-blind, randomized, placebo-controlled study of mometasone furoate nasal spray in pediatric subjects with perennial allergic rhinitis
    Medical condition: perennial allergic rhinitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004922-16 Sponsor Protocol Number: P06333 Start Date*: 2015-02-24
    Sponsor Name:Corporation Schering-Plough K.K.
    Full Title: A study of long-term (12-24 weeks) administration of mometasone furoate nasal spray in pediatric subjects with perennial allergic rhinitis (Protocol No. P06333)
    Medical condition: Perennial Allergic Rhinitis
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002414-12 Sponsor Protocol Number: 12082.101 Start Date*: Information not available in EudraCT
    Sponsor Name:PARI Pharma GmbH
    Full Title: A randomised, open, controlled pilot study to investigate the efficacy and safety of Buparid/PARI SINUS versus Budes® Nasal Spray in the therapy of Chronic Rhinosinusitis (CRS) with polyposis nasi ...
    Medical condition: Chronic Rhinosinusitis (CRS) with polyposis nasi
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004936-52 Sponsor Protocol Number: CASK0119 Start Date*: 2020-04-17
    Sponsor Name:Cassella-med GmbH & Co KG
    Full Title: Prospective, controlled, randomized double-blind study to determine the sensory perception of two nasal sprays using the model of treatment of post-operative complaints after surgery on the nasal m...
    Medical condition: Post-operative nasal blockage following surgical interventions of the nasal cavity.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000267-72 Sponsor Protocol Number: D3252C00002 Start Date*: 2021-09-07
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps ...
    Medical condition: Patient with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) HU (Trial now transitioned) FR (Completed) PL (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002499-35 Sponsor Protocol Number: RHINNOVATE^HA Start Date*: 2022-09-29
    Sponsor Name:Jadran - galenski laboratorij d.d. (JGL)
    Full Title: Multicentre, randomized, double-blind, parallel design clinical trial of efficacy, safety and tolerability of Xylometazoline + Sodium Hyaluronate nasal spray, compared to Xylometazoline, Sodium Hya...
    Medical condition: Treatment of acute viral rhinosinusitis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003675-61 Sponsor Protocol Number: D3252C00001 Start Date*: 2017-12-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients with Severe Nasal Polyposis
    Medical condition: Nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10028754 Nasal polyp LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) AT (Completed) BE (Completed) HU (Completed) PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002421-30 Sponsor Protocol Number: 12082.102 Start Date*: 2014-06-06
    Sponsor Name:PARI Pharma GmbH
    Full Title: A randomised, open, controlled pilot study to investigate the potential of Buparid/PARI SINUS versus Budes® Nasal Spray to avoid or postpone sinus surgery in adult patients with Chronic Rhinosinu...
    Medical condition: Chronic Rhinosinusitis (CRS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000195-38 Sponsor Protocol Number: D3252C00004 Start Date*: 2020-11-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab for the Prevention of Recurrence of Nasal Polyps Following Surgical Rem...
    Medical condition: Nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10028754 Nasal polyp LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000164-17 Sponsor Protocol Number: tobra nasal CF pilot Start Date*: 2008-08-13
    Sponsor Name:University of Jena
    Full Title: Nasale Inhalation von Tobramycin mit dem Pari Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich. Nasal inhalation of tobramycin by the Pari ...
    Medical condition: subjects with cystic fibrosis and pseudomonas aeruginosa colonization in the upper airways
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005461-19 Sponsor Protocol Number: 11/06/OXD/TP3 Start Date*: 2006-12-20
    Sponsor Name:Zentiva a.s.
    Full Title: A Randomized, Double Blind, Placebo Controlled Multicenter Study to Assess the Tolerability and Safety of ANTIRIN® nasal spray and drops in two Age Groups of Children with Acute Rhinitis
    Medical condition: Rinitis acuta
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039083 Rhinitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004907-22 Sponsor Protocol Number: AUG117150 Start Date*: 2016-08-03
    Sponsor Name:Medicines Development (Infectious Diseases)
    Full Title: A multicenter, open-label study to assess the efficacy and safety of potassium clavulanate/amoxicillin (CVA/AMPC 1:14 combination) in the treatment of [Japanese] children with acute bacterial rhin...
    Medical condition: Acute Bacterial Rhinosinusitis
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001259-63 Sponsor Protocol Number: Pollenvaccine2014-01-15 Start Date*: 2016-03-09
    Sponsor Name:Department of Clinical Science, Intervention and Technology, Karolinska Institute
    Full Title: Intralymphatic immunotherapy in increasing doses up to 10 000 SQ-U -a human randomized clinical trial
    Medical condition: Patients with severe to moderate Allegic rhinitis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005876-33 Sponsor Protocol Number: 13/05/OXD/TP3 Start Date*: 2006-05-10
    Sponsor Name:Zentiva a.s.
    Full Title: A Randomised, Double Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of nasal spray ANTIRIN® and NASIC® in the Treatment of Acute Viral Rhinitis
    Medical condition: Rhinitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039083 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-004889-18 Sponsor Protocol Number: 1.3 Start Date*: 2022-04-21
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of Dupilumab in patients with aspirin-exacerbated respiratory disease (AERD) -A single-center prospective pilot study
    Medical condition: Aspirin-exacerbated respiratory disease (AERD), also known as Samter's Triad or Widal's triad, comprises the triad of allergic asthma, chronic rhinosinusitis with nasal polyps (CRswNP) and nonstero...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004730-18 Sponsor Protocol Number: OSLER_TIMOLOL Start Date*: 2019-12-11
    Sponsor Name:University Hospital Regensburg
    Full Title: The influence of Timolol Nasal Spray on Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
    Medical condition: 2) hereditary hemorrhagic telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-005074-24 Sponsor Protocol Number: Feb-02 Start Date*: 2005-02-23
    Sponsor Name:Febena Pharma GmbH
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF AN OINTMENT FORMULATION CONTAINING DEXAMETHASONE IN PATIENTS WITH RHINOSINUSITIS A CLINICAL PHASE IV ...
    Medical condition: Patients with allergy-induced, non-infectious diseases of the nasal mucosa (e. g. hay fever) and the sinuses.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052106 Rhinosinusitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000186-76 Sponsor Protocol Number: MK-4117-200 Start Date*: 2017-01-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects with Perennial Allergic Rhinitis.
    Medical condition: Perennial allergic rhinitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004855 10034382 Perennial allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-017997-19 Sponsor Protocol Number: AGO/2009/014 Start Date*: 2010-08-25
    Sponsor Name:Ghent University Hospital
    Full Title: Influence of oral doxycycline on wound healing after endonasal endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposis: a double-blind randomized placebo-controlled trial.
    Medical condition: Chronic rhinosinusitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:26:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA